share_log

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A：持股變動聲明(修正)-高管 Dogan Meeshanthini
美股SEC公告 ·  2024/10/08 08:46

Moomoo AI 已提取核心訊息

On September 6, 2024, Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings, Inc. [CDIO], completed a purchase of company stock. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Dogan's direct holdings in the company increased to a total of 1,655,429 shares. The purchase, conducted on the open market, reflects the CEO's direct investment in the company's stock and is a matter of record for investors monitoring insider activity.
On September 6, 2024, Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings, Inc. [CDIO], completed a purchase of company stock. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Dogan's direct holdings in the company increased to a total of 1,655,429 shares. The purchase, conducted on the open market, reflects the CEO's direct investment in the company's stock and is a matter of record for investors monitoring insider activity.
2024年9月6日，Cardio Diagnostics Holdings, Inc. [CDIO]的首席執行官Meeshanthini Dogan完成了對公司股票的購買。該交易涉及以每股0.29美元的價格購買了68,965股普通股。在此交易之後，Dogan在公司的直接持股增加至總共1,655,429股。這次在公開市場上進行的購買反映了CEO對公司股票的直接投資，並對監控內幕交易的投資者來說是一項記錄。
2024年9月6日，Cardio Diagnostics Holdings, Inc. [CDIO]的首席執行官Meeshanthini Dogan完成了對公司股票的購買。該交易涉及以每股0.29美元的價格購買了68,965股普通股。在此交易之後，Dogan在公司的直接持股增加至總共1,655,429股。這次在公開市場上進行的購買反映了CEO對公司股票的直接投資，並對監控內幕交易的投資者來說是一項記錄。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Organovo Holdings
    ONVO
    -- 1.270
    Silexion Therapeutics
    SLXN
    -- 1.230
    LAVA Therapeutics
    LVTX
    -- 1.340
    Dominari Holdings
    DOMH
    -- 9.900
    GT Biopharma
    GTBP
    -- 2.4600
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股集體大漲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 $阿里巴巴 (BABA.US)$ 第三財季總營收同比增長8%，AI助推阿裏雲收入大漲13%。 🎙️討論： 1. 阿裏巴巴Q3單季報發布後股價飆升。此時是否是入場良 展开
    中國股票的瘋狂反彈暫停了？華爾街仍然對熱門股下注